Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

174.00 -7.18 (-3.96%)
Official Closing Price Updated: 4:15 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
48 49 Next >
Ron DeSantis Escapes Car Accident Unhurt En Route To Campaign Event, TikTok Takes On Twitter, Analysts Expect Nvidia's AI Revenues To Reach $300B In Five Years: Today's Top Stories
The Hill Ron DeSantis Escapes Car Accident Unhurt En Route To Campaign Event 
Via Benzinga
WMT Stock Alert: Is Walmart Really Worth $210?
Walmart (WMT) stock is in the news Tuesday as investors react to the latest coverage from Piper Sandler analyst Edward Yruma. 
Via InvestorPlace
MBLY Stock Alert: Morgan Stanley Restarts Mobileye Coverage
Mobileye (MBLY) stock is on the move Tuesday after Morgan Stanley analyst Adam Jonas renewed coverage of the company's shares. 
Via InvestorPlace
Biogen Layoffs 2023: What to Know About the Latest BIIB Job Cuts
Biogen (BIIB) layoffs are on the way as the company seeks further profits with its upcoming Alzheimer's disease drug launch. 
Via InvestorPlace
Biogen Inc. Tops Q2 Earnings And Revenue Estimates
Biogen Inc. came out with quarterly earnings of $4.02 per share. 
Via Talk Markets
Better Big Biotech Buy: Vertex vs. Biogen
These companies have a track record of billion-dollar earnings. 
Via The Motley Fool
Biogen Earnings Preview
Via Benzinga
Biogen Unusual Options Activity
Via Benzinga
Biogen Q2 Earnings Tops Expectations, Shift Resources To Higher Value Area(s), Layoff 1K Staff
Biogen Inc (NASDAQ: BIIB) posted Q2 FY23 sales of $2.46 billion, beating the con 
Via Benzinga
Nasdaq Futures Rise Ahead Of Microsoft, Alphabet Earnings: Analyst Warns Of Volatility From Fed's Message 'Crafting'
Via Benzinga
All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings
Analysts expect Biogen to report a a decline in both profits and sales in Q2. 
Via Investor's Business Daily
Goldman Sachs, Charles Schwab And This Healthcare Stock On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Biogen Inc. 
Via Benzinga
(BIIB) - Analyzing Biogen's Short Interest
Via Benzinga
Is Biogen Stock a Buy Now?
The biotech hasn't been the best investment recently. 
Via The Motley Fool
Should You Buy the Dip With Biogen Stock Right Now?
It's expected to grow, but things might not work out precisely as planned. 
Via The Motley Fool
P/E Ratio Insights for Biogen
Via Benzinga
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023
From Biogen Inc.
Via GlobeNewswire
Acumen Soars on Alzheimer's Study...Street Sees It Doubling
Will the $11.00 level be a double-top ceiling…or can Acumen Pharmaceuticals build momentum and climb towards its $25.00 IPO price? 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
These 2 Numbers Should Scare Every Biogen Shareholder
There are a couple of pieces of evidence that Biogen's long-term strategy isn't working. 
Via The Motley Fool
7 Stocks That AI Says Will Make You a Millionaire by 2025
These seven millionaire-maker stocks are changing hands at deeply undervalued levels. As their growth re-accelerates, so will your portfolio. 
Via InvestorPlace
Biogen Just Reached a Big Milestone. Why Isn't the Stock Rising?
Biogen shares are little changed year to date. 
Via The Motley Fool
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $4,900 Today
Via Benzinga
Why Isn't Biogen Stock Soaring After This Major FDA Approval?
Is the stock a good contrarian buy? 
Via The Motley Fool
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi
Biogen's shares decline after approval of Alzheimer's treatment Leqembi, which modestly slows cognitive decline. Analysts see hurdles to the rollout. 
Via MarketBeat
Exposures Product Safety
Mixed Jobs Data; Fed Governors Want More Interest Rate Hikes; US, China Spat Rattles Semiconductor Sector: The Week In The Markets
Via Benzinga
Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts
The FDA approved a supplemental marketing application for Biogen Inc (NASDAQ: BIIB)-Eisai Co Ltd (OTC: ESALY) supporting the traditional approval of Leqembi (lecanemab-irmb), making it the first and... 
Via Benzinga
FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline
The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval. 
Via Benzinga
Stock Market Rally Pulls Back As Yields Jump; Tesla, Meta In Focus: Weekly Review
Automakers rallied on sales while Meta's Threads had a big launch. 
Via Investor's Business Daily
FSLR Stock Alert: The $1 Billion Reason First Solar Is Up Today
First Solar (FSLR) stock is rising higher on Friday after the solar energy company announced a $1 billion revolving credit facility. 
Via InvestorPlace
Why Is Alibaba (BABA) Stock Up Today?
Alibaba (BABA) stock is on the rise Friday as investors react to a few pieces of news considering the Chinese e-commerce giant. 
Via InvestorPlace
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
48 49 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.